Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute
NCT04309331 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2020-03-16
Summary
The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.
Conditions
- PKU
- Phenylketonurias
- Inborn Errors of Metabolism
- Metabolic Disease
Interventions
- DIETARY_SUPPLEMENT
-
Motion
Amino acid based protein substitute
Sponsors & Collaborators
-
Dr. Schär AG / SPA
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 3 Years
- Max Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-01
- Primary Completion
- 2018-09-19
- Completion
- 2018-09-19
Countries
- United Kingdom
Study Locations
More Related Trials
-
Evaluation of PKU Explore
NCT03168399 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Phe Fluctuation in PKU Pts Treated With PKU GOLIKE Versus Standard Amino Acid Protein Substitute.
NCT05487378 ·Status: COMPLETED ·Phase: NA
-
GMP Drink for PKU Study
NCT02915510 ·Status: COMPLETED ·Phase: NA
-
Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response
NCT00841100 ·Status: COMPLETED ·Phase: PHASE2
-
Phenylketonuria and Hyperphenylalaninemia Nutrition Study
NCT01879995 ·Status: COMPLETED
-
Natural History Clinical Study in Adult PKU
NCT04768348 ·Status: TERMINATED
-
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
NCT06523400 ·Status: RECRUITING ·Phase: PHASE3
-
A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
NCT06147856 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Antioxidant Signature in Adult Patients With Phenylketonuria
NCT02212288 ·Status: COMPLETED
-
Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
NCT07220265 ·Status: RECRUITING ·Phase: NA
-
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
NCT03759665 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)
NCT04085666 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients
NCT04256655 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phenylketonuria, Oxidative Stress, and BH4
NCT01395394 ·Status: TERMINATED ·Phase: PHASE2
-
Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period
NCT01082328 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Study of Endothelial Dysfunction in Phenylketonuria
NCT02176603 ·Status: COMPLETED
-
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
NCT03520751 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease
NCT00004314 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
NCT02790034 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Nutritional and Neurotransmitter Changes in PKU Subjects on BH4
NCT00688844 ·Status: COMPLETED
-
Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.
NCT05827536 ·Status: TERMINATED ·Phase: NA
-
Kuvan® in Phenylketonuria Patients Less Than 4 Years Old
NCT01376908 ·Status: COMPLETED ·Phase: PHASE3
-
PANDA: PKU Amino Acid Evaluation
NCT04086511 ·Status: COMPLETED
-
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
NCT00838435 ·Status: COMPLETED ·Phase: PHASE3